Jun 15, 2021

Featuring perspectives from Drs Sagar Lonial and Krina K Patel, including the following topics:

• Faculty Presentation — Sagar Lonial, MD
  • Diagnosis, risk stratification and role of cytogenetics in multiple myeloma (MM) (0:00)
  • ENDURANCE (E1A11): Results of a Phase III trial evaluating KRd (carfilzomib, lenalidomide and dexamethasone) versus Ienalidomide, bortezomib and dexamethasone (RVd) as initial therapy for patients with MM (5:16)
  • Findings from Phase III trials evaluating daratumumab-containing front-line regimens for newly diagnosed MM (7:04)
  • Emerging results from Phase III studies evaluating elotuzumab and ixazomib as components of induction therapy (8:40) 
  • Factors to consider in the treatment selection for newly diagnosed versus relapsed disease (10:16)
  • Published research with isatuximab and with selinexor for relapsed/refractory MM (12:41)
  • Mechanism of action of selinexor; role of KRd and daratumumab for patients with high-risk MM (15:27)
  • Case: A man in his early 60s with standard-risk MM receives RVd and daratumumab on the GRIFFIN trial (23:50)
• Faculty Presentation — Krina K Patel, MD, MSc
  • Compositional and mechanistic similarities and differences among, efficacy and safety outcomes with and ongoing investigation of various B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy platforms in MM (36:26)
  • Efficacy and safety results from studies evaluating belantamab mafodotin alone (DREAMM-2) or in combination with bortezomib/dexamethasone (DREAMM-6) for relapsed/refractory MM (59:51)
  • Available data with novel anti-BCMA bispecific T-cell engagers for patients with MM (1:04:01)
  • Published efficacy and safety findings with venetoclax for MM; correlation between t(11;14) status and response (1:07:07)
  • Activity and safety of next-generation immunomodulatory agents observed in patients with heavily pretreated MM; other novel strategies in clinical development (1:11:27)
• Discussion of Investigator Survey with Dr Lonial and Dr Patel
  • Induction and maintenance therapy for newly diagnosed MM (1:16:09)
  • Management of relapsed/refractory disease (1:41:48)
• FDA approval of the antibody-drug conjugate belantamab mafodotin and role of BCMA-directed CAR T-cell therapies in MM (1:51:22)
• Future developments and novel investigational approaches in MM (2:07:14)

CME information and select publications